Literature DB >> 18955438

Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies.

Julien Lejeune, Gilles Thibault, David Ternant, Guillaume Cartron, Hervé Watier, Marc Ohresser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18955438     DOI： 10.1200/JCO.2008.19.4118

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  22 in total

1.  Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.

Authors:  Daniel O Persky; David Dornan; Bryan H Goldman; Rita M Braziel; Richard I Fisher; Michael Leblanc; David G Maloney; Oliver W Press; Thomas P Miller; Lisa M Rimsza
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 2.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 3.  Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

Authors:  Ezogelin Oflazoglu; Laurent P Audoly
Journal:  MAbs       Date:  2010-01-30       Impact factor: 5.857

4.  Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

Authors:  David Ternant; Emilie Hénin; Guillaume Cartron; Michel Tod; Gilles Paintaud; Pascal Girard
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

5.  FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.

Authors:  Julien Lejeune; Benoît Piègu; Valérie Gouilleux-Gruart; Marc Ohresser; Hervé Watier; Gilles Thibault
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

6.  Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.

Authors:  Ningyan Zhang; Liming Liu; Calin Dan Dumitru; Nga Rewa Houston Cummings; Michael Cukan; Youwei Jiang; Yuan Li; Fang Li; Teresa Mitchell; Muralidhar R Mallem; Yangsi Ou; Rohan N Patel; Kim Vo; Hui Wang; Irina Burnina; Byung-Kwon Choi; Hans E Huber; Terrance A Stadheim; Dongxing Zha
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

7.  Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.

Authors:  D Hannani; C Locher; T Yamazaki; V Colin-Minard; M Vetizou; L Aymeric; S Viaud; D Sanchez; M J Smyth; P Bruhns; G Kroemer; L Zitvogel
Journal:  Cell Death Differ       Date:  2013-06-07       Impact factor: 15.828

8.  Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.

Authors:  Wen-Kai Weng; Ronald Levy
Journal:  Leuk Lymphoma       Date:  2009-05

Review 9.  Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.

Authors:  Matthias Peipp; Michael Dechant; Thomas Valerius
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

Review 10.  Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.

Authors:  Josée Golay; Gianpietro Semenzato; Alessandro Rambaldi; Robin Foà; Gianluca Gaidano; Enrica Gamba; Fabrizio Pane; Antonello Pinto; Giorgina Specchia; Francesco Zaja; Mario Regazzi
Journal:  MAbs       Date:  2013-08-08       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.